RZLT vs. SPRY, EVO, TVTX, ANIP, MESO, OCUL, BGM, GPCR, AMPH, and CALT
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include ARS Pharmaceuticals (SPRY), Evotec (EVO), Travere Therapeutics (TVTX), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs.
Rezolute (NASDAQ:RZLT) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Rezolute currently has a consensus target price of $11.83, indicating a potential upside of 168.33%. ARS Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 111.03%. Given Rezolute's higher probable upside, equities research analysts plainly believe Rezolute is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals' return on equity of -22.56% beat Rezolute's return on equity.
Rezolute has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for ARS Pharmaceuticals and 1 mentions for Rezolute. ARS Pharmaceuticals' average media sentiment score of 1.70 beat Rezolute's score of 1.35 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.
Rezolute received 49 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 83.33% of users gave ARS Pharmaceuticals an outperform vote while only 79.57% of users gave Rezolute an outperform vote.
83.0% of Rezolute shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 18.4% of Rezolute shares are held by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ARS Pharmaceuticals has higher revenue and earnings than Rezolute. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Summary
ARS Pharmaceuticals beats Rezolute on 10 of the 16 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy RZLT Stock Free RZLT Stock Alerts